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ABST R ACT  - Purpose: Lyme disease has become an increasingly important global public health concern. 
Method: A  narrative review was conducted and designed to present a broad perspective on Lyme disease, and 
describe its history and development in terms of clinical care and public health implications. A  structured 
literature search was conducted based on the question; what is currently known about Lyme disease? R esults: 
The narrative review is presented in chronological order in terms of a summary of the history of Lyme disease, 
the complexities of clinical diagnosis, the problematic interpretation of serologic testing, the conflicting 
guidelines for diagnosis, treatment and management of chronic Lyme, and benefits of antibiotic treatment. 
Conclusion: Despite growing global incidence of the Lyme disease, treatment has not attracted 
pharmaceutical investment, and the evidence base and international guidelines for treatment and management 
of chronic Lyme continue to be conflicting and controversial. The challenges of this immune mediated tick 
borne disease for public health policy and clinical practice are summarised, alongside directions for future 
research. 
_______________________________________________________________________________________  
 
INT R ODUCT ION 
 
Lyme disease has become an increasingly 
important global public health concern.
1,2,3
 Lyme 
disease was originally identified in Lyme, 
Connecticut, and was based on an unusual cluster 
of children with juvenile rheumatoid arthritis.
4
 
Geographic distribution and incidence of Lyme 
disease is on the increase worldwide, and has 
become the most common vector-borne illness in 
Europe particularly Austria, Czech Republic, 
Germany, Slovenia, and Switzerland; and in China, 
Australia, Africa and North East United States 
(US).
2,5,6,7,8,9,10,11
 Lyme disease or Lyme Borreliosis 
is caused by spirochaetes of the B burgdorferi 
sensu lato o species complex and is transmitted by 
infected Ixodes scapularis or Ixodes ricinus 
ticks.
5,6,7,10,11
 In 2000, Rowe reported that Lyme 
disease in Europe is caused by any one of three tick 
borne spirochetes in the B. burgdorferi sensu lato 
complex— B burgdorferi sensu stricto, B afzelii, 
and B garinii, whereas in the US, only the first 
species is involved. A  new Borrelia genospecies 
causing Lyme Borreliosis has since been identified 
in the US.
12
 In 2016, it is estimated that between 20 
and 25% of ticks in Europe are infected with B 
burgdorferi sensu lato, with risk of symptomatic 
infection after a tick bite estimated to be between 1 
and 3%.
13
 Co-infection with other pathogens 
(Ehrlichia, Neoehrlichia, Rickettsia, Babesia and 
Theileria) is also on the increase worldwide. There 
is no vaccine to prevent Lyme Borreliosis.
11
 
Prevention strategies centre on use of insect  
 
repellents, application of pesticides and removal of 
ticks, with no pharmacological prevention strategy 
available.
10
 
 
ME T HODS 
 
A  narrative review was conducted and designed to 
present a broad perspective on Lyme disease, and 
describe its history and development in terms of 
clinical care and public health implications. A 
structured literature search was conducted based 
on the question; what is currently known about 
Lyme disease? Search terms include Lyme, Lyme 
Borreliosis, Chronic Lyme Disease, Borrelia 
burgdorferi, and tick borne disease. Studies were 
excluded if not in the English language and if they 
did not present detail on Lyme disease. There was 
no restriction on date range, and all types of 
articles, including opinion pieces were included. 
The narrative review is presented in the form of an 
Editorial and in chronological order in terms of the 
following key themes; a summary of the history of 
Lyme disease, the complexities of clinical 
diagnosis, the problematic interpretation of 
serologic testing, the conflicting guidelines for 
diagnosis, treatment and management of chronic 
Lyme, and benefits of antibiotic treatment. 
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2 
R E SUL T S 
 
History of the Disease 
Lyme Borreliosis is an immune mediated disease 
secondary to exposure to Borrelia burgdorferi.
4,5
 It 
is a complex disease where both the specific 
disease causing organism and the host responses 
appear to affect the disease course.
14
 Different 
strains of Borrelia are exist with clinical 
manifestations of Lyme disease (and co-infections) 
varying between the US and Europe, and 
characterised by a diverse range of acute and 
chronic manifestations.
15
 It is similar to another 
spirochetal disease, namely syphilis, in that it can 
be divided into three key stages; early; early 
disseminated and late disseminated manifestations 
of the disease.
7
 Infection progresses to 
disseminated disease in approximately 50% of 
untreated individuals.
16,17,18,19,20,21,22,23
 CDC 
estimates that between 10 and 20% of patients who 
are appropriately treated for infection will remain 
symptomatic for a variable and unspecified length 
of time.
18
 The public health impact of Lyme 
disease where estimated (in the Netherlands) 
carries a substantial burden of disease.
24
   
 
T he Complexities of C linical Diagnosis  
The clinical diagnosis of Lyme is based on clinical 
manifestations and appropriate serology.
4
  Early 
manifestations include nonspecific signs and 
symptoms such as headache, fever and myalgias.
10 
 
The disease typically commences with an 
erythematous rash known as erythema migrans 
(EM),
4,25
 due to local skin infection which is 
observed in between 60–80% of infected people 
several days to weeks after the tick bite.
10,11
  The 
EM rash expands by 2-3cm per day over several 
days with some parts clearing to result in a bulls 
eye image.
10
 Diagnosis of Lyme borreliosis is 
based on patient history of potential exposure to 
ticks, infection risk with B. burgdorferi sensu lato, 
the EM rash and development of specific 
symptoms, exclusion of other causes and 
appropriate serological or other diagnostic tests 
indicating a positive a positive Borrelia 
serology.
6,7,26
 Epidemiologic context is extremely 
important, with the probability of a tick bite 
(likelihood of contracting Lyme disease) highest in 
individuals who spend time outdoors (particularly 
in wooded, brushy, or grassy habitats) in a 
geographically endemic area, and at certain times 
of year.  Hence, patient travel history is especially 
important in clinical practice, as individuals may 
be infected not locally, but as part of a visit abroad 
to a geographic areas endemic for Lyme or co 
infections.
18,27,28
  Dissemination occurs soon after 
the tick bite, but signs and symptoms of late disease 
may not be evident for weeks, months or even 
years.
3,28,29,30,31
 Early dissemination of this multi-
systemic, multistage, inflammatory disease can 
involve the skin, muscles, joints or the central 
nervous and peripheral nervous systems.
32
 The 
infecting pathogen can spread to organs and other 
tissues, and can severely affect the patients nervous 
system, joints, heart and skin.
4,5,11,26,32
 Arthritis is 
the most common late state symptom in the US, but 
in Europe, radiculomyelitis, peripheral 
neuropathy, or chronic skin involvement 
(acrodermatitis chronica atrophicans) is more 
common.
14
 Lyme carditis is a real diagnostic and 
therapeutic challenge for clinicians.
5
 It is not 
uncommon for patients to initially present with late 
stage disease.
3
 This complicates clinical diagnosis, 
with additional complicating factors making 
diagnosis problematic including the negation of 
tick bite, absence of EM, atypical clinical picture, 
onset of symptoms outside of the period of tick 
activity, and negative serological results in the 
initial stages of the disease.
5,10,33 
 More recently, the 
debate centres around the ICD system for Lyme 
Borrelisis, where the diverse range of 
manifestations, stages and complications of this 
disease are not stated, and are restricted to the acute 
form of Lyme.
2 
 
T he Problematic Interpretation of Serologic 
T esting 
Complications exist around the role of serologic 
testing in the clinical diagnosis and management of 
the patient.
3
 Serologic tests, enzyme-linked 
immunosorbent assays (ELISAs), and Western 
blots are used by clinicians to diagnose untreated 
Lyme disease.
34,35
 Most commercial laboratories 
will perform both IgG and IgM Western 
blots.
18,36,37
  Interpretation of serology is however 
problematic and centres on assay heterogeneity, 
high background sero-prevalence in endemic 
areas, lack of clinical validation of assays in 
Europe, accuracy of antibody tests, and the 
presence of diverse strains of Borrelia in the US 
and Europe, all of which contribute to delays in 
diagnosis and patient treatment.
3,38,39,40,41,42,43
 B. 
burgdorferi antibody testing should be performed 
only in patients presenting with clinical signs 
suggestive of infection.
1
 Complexities lie in the 
early stage of disease where the antibody test may 
not indicate a positive result, rendering treatment 
ineffective. It is important that serologic features 
are interpreted correctly in order to avoid a false 
diagnosis of Lyme disease.
4,44
 Serologic features 
are often misinterpreted, and false positives can 
occur if confirmatory laboratory testing is not 
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3 
conducted.
4
,
33
 Complexities additionally occur 
when clinicians use serology to rule in or out 
persistent Lyme disease,
3
 with some disagreement 
on this approach with current evidence suggestive 
that none of the available clinical serologic tests 
can determine if a patient has ongoing infection. 
Positive serology in patients who have been treated 
for Lyme is not indicative of ongoing infection.
3,18
  
Finally, it is ‘not all about Lyme’, and many 
clinicians fail to test for other co-infections with 
similar clinical manifestations as Lyme, both tick 
borne (Babesia, Rickettsiae, Anaplasma, 
Bartonella, Q fever) and non-tick borne 
(Chlamydia pneumonia, Mycoplasma pneumonia).  
Hence, there remains a clear difficulty in the lack 
of a ‘gold standard’ as there is no antigen specific 
or PCR specific test commercially available 
worldwide for clinicians to use, and testing relies 
on imperfect indirect immunological measures to 
assist with diagnosis.  Rapid detection using tick 
tests for B burgdorferi sensu lato infection are 
limited in terms of sensitivity and specificity and 
not recommended to guide treatment.
13 
 
Conflicting Guidelines for Diagnosis, 
T reatment and Management of Chronic L yme 
Despite growing global incidence of the Lyme 
disease, treatment has not attracted pharmaceutical 
investment, and the evidence base and 
international guidelines for treatment and 
management of chronic Lyme continue to be 
conflicting and controversial.
1,45,46
 Treatment is 
generally with antibiotics such as doxycycline, 
amoxicillin or cefuroxime (2-4 weeks) and is 
generally more successful for early forms of the 
disease.
3,9,11,28
 Early short-term prophylaxis with 
oral doxycycline is however contraindicated in 
children under 8 years and pregnancy.
10
 
Azithromycin is a potential antibiotic agent for 
prophylactic topical use.
47,48,49
 Guidelines are 
conflicting. CDC
8 
recommends according to the 
Infectious Disease Society of America (IDSA) 
guidelines for the treatment of Lyme disease. 
These guidelines recommend early prophylactic 
antibiotic treatment with doxycycline if patients 
have a recognized tick that has been present for 
over 36 hours judged from the degree of 
engorgement of the tick, with treatment started 
within 72 hours of the tick being removed, there is 
evidence of B. burgdorferi in over 20% of ticks in 
the area where the tick bite occurred and 
doxycycline is not contraindicated. The guidelines 
stress the importance of identifying the Ixodes 
species of tick before treatment may begin. This 
however may not always be possible if the tick has 
been removed by the patient. V ery few countries 
have the expertise to be able to make such 
identification, and clinicians may advocate that 
patients who have a tick-borne infection for 
periods shorter than 36 hours would also benefit 
from antibiotic treatment.  IDSA
39
 recommend 
antimicrobial treatment with oral doxycycline 
when erythema migrans develops. However, this 
approach is associated with systematic drug 
exposure for 10-21 days, with sub clinical infection 
not effectively treated and potentially allowing the 
disease to progress.
10
 Failures can however occur 
with shorter course treatments for early Lyme 
infection.  Hence, guidelines for the management 
of patients with Lyme disease developed by the 
International Lyme and Associated Diseases 
Society (ILADS) and the German Borreliosis 
Society
50
 favour longer term, combination 
antibiotic therapies. 
Controversy continues around whether 
infection persists and causes chronic symptoms, 
despite antimicrobial treatment.
9
 The debate 
centres on whether clinical manifestations are 
active infection or post-infectious auto-immunity. 
Patients with ongoing persistent symptoms after 
the standard 2-4 week recommended antibiotic 
therapy have been denied further antibiotic 
treatment.
46
 This is a result of the ongoing 
controversy around whether long term chronic 
infection with the Lyme spirochete, B.burgdorferi, 
and associated tickborne pathogens is exists.
9,46,51
 
Clinical challenges therefore exist in the treatment 
of disparate patient groups, which include patients 
with untreated late-stage infection (late 
neuroborreliosis), patients with subjective 
symptoms that persist after treatment ('post-
treatment Lyme disease syndrome': PTLDS), and 
patients with unexplained subjective complaints 
which may or may not be accompanied by positive 
test results for B. burgdorferi infection in serum 
(here called 'Chronic Lyme disease: CLD)
1,52
 CLD 
is used to describe a range of atypical symptoms 
such as fatigue and chronic pain which occur due 
to lengthy B.burgdoferi infection.
53,54
 CLD 
currently lacks an accepted clinical definition, and 
generally diagnosed patients have other illnesses.
1
 
PLDS describes patients who, after treatment for 
Lyme disease with an accepted treatment regimen, 
present within 6 months or many years later, with 
non-specific symptoms such as fatigue and 
widespread musculoskeletal pain. Complexities 
centre on the fact that CLD and PSLD share similar 
clinical symptoms to F ibromyalgia and Chronic 
Fatigue Syndrome, and with misdiagnosis of 
F ibromyalgia and Chronic Fatigue Syndrome 
occurring in patients with CLD/PSLD.
28,51,52,55
 It is 
uncertain what pathophysiologic mechanisms (or 
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multiple mechanisms) are responsible for Lyme 
disease.
3
 These include presence of other untreated 
infections; a post-infectious state; permanent or 
temporary tissue damage; secondary conditions 
triggered by the initial infection and persisting 
despite bacterial eradication; immune dysfunction 
due to auto-antibodies or unregulated 
inflammation, and/or persistent B burgdorferi 
infection. Supporting evidence for most of these 
mechanisms are limited.
28,45
 There is support for all 
potential mechanisms, with exception of persistent 
infection,
18,28,56
 with some maintaining that 
persistent infection is a demonstrated cause of 
persistent Lyme disease, with other mechanisms 
playing a role.
45,57
 
 
Benefits of Antibiotic T reatment. 
Controversies are evident around clinical 
management and the potential benefits of antibiotic 
treatment.
3
 The challenges of Lyme disease centre 
on the lack of evidence to support use of antibiotics 
for longer than 4 weeks, or the persistence of 
spirochaetes in treated patients.
4,11
 There have been 
a number of ‘point and counterpoint’ editorials on 
the benefits (or not) of longer treatment for Lyme 
disease.
46,58,59
 IDSA and CDC do not recommend 
prolonged treatment with antibiotics
18,28 
and some 
studies advocate against prolonged treatment in 
these patients.
11,60,61
 Others in contrast indicate that 
retreatment
45,62 
and prolonged antibiotic therapy 
may be useful and justifiable in patients with 
persistent Lyme disease symptoms, and with 
coinfection with tick borne agents.
46
 Frequent 
treatment relapses and failures with short term 
therapy are documented by other authors.
31,63,64,65
  
The safety of long term antibiotic use, for three to 
six months, or longer, has now been demonstrated 
and can provide a new possible avenue for 
treatment.
50,66,67
 Longer courses of antibiotic 
treatment and re-treatment are reported to incur 
benefit for Lyme disease patients with persistent 
symptoms.
57,68,69,70
 A  limited number of NIH-
funded trials have been conducted on the treatment 
of chronic Lyme disease,
71,72,73
 with two of the 
three clinical trials demonstrating that re-treatment 
improved some patients’ measures, such as fatigue 
and pain.
71,73
 Others have shown improvement in 
cognitive function, in those with Lyme 
encephalopathy.
62
 Antibiotic treatment is also 
effective in about 90% of patients with Lyme 
arthritis.
74
 Hence, the challenge of having no ‘gold 
standard’ to determine ‘objective markers’ makes 
recommended clinical pathways debatable. 
 
 
 
DISCUSSION 
 
The author recognises that narrative reviews whilst 
useful for providing a broad historical overview of 
a public health topic, are a dynamic process and are 
therefore not reproducible, and may contain 
selection bias. That said, this Editorial intends to 
bring together key themes pertaining to Lyme 
disease, and has highlighted and drawn attention to 
the complexities of clinical diagnosis of Lyme 
disease, interpretation of definitions and treatment 
guidelines, and challenges for clinical practice and 
public health. Lyme disease represents a serious 
challenge for global and national health 
organizations.
1,2,3,45,75
 It is a complex and 
debilitating illness with patients experiencing both 
acute and persistent manifestations, which impair 
quality of life, and yet are poorly understood.
45
 
Despite growing global incidence of the Lyme 
disease, treatment has not attracted pharmaceutical 
investment, and the evidence base and 
international guidelines for treatment and 
management of chronic Lyme continue to be 
conflicting and controversial. 
Challenges for clinicians centre on the lack of 
sensitive laboratory techniques available to 
optimally diagnose, and the debate as to 
recommended management of the disease as to 
whether conditions can become chronic. Patients 
suffering from this disease are in an unenviable 
position, caught between clinicians from opposing 
peer reviewed clinical guidelines generated by 
IDSA and ILADS. Patients have established their 
own special groups to provide advocacy for their 
cause.  Polarisation within the different Lyme 
related guidelines and debates that are circulating 
within different special interest groups 
continues
18,76,77,78,79,80,81,82,83
 and contribute to a 
unique and critical public health phenomenon 
whereby patients and individuals suffer. In the 
context of public health policy, public awareness 
raising warrants a stronger approach,
2
 including in 
terms of governmental travel guidance yielding 
accurate health warnings for travellers in the 
countries and regions under the wide global range 
of borreliosis.
45
 It is vitally important to utilize an 
enhanced set of ICD codes to ensure quality of 
borreliosis surveillance to inform national 
prevalence data, burden of disease estimates, 
public health policy  and the direction of patient 
and population awareness raising.
2
  Enhanced 
epidemiological studies of the prevalence of 
infections in different locations, in different 
wildlife populations and in ticks themselves are 
warranted, alongside rigorous investigations into 
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5 
the clinical conditions of individuals found to be 
positive.  
Further it remains paramount to support 
investment of resources to better understand the 
disease pathway and its pathophysiologic 
mechanisms, identify variables associated with 
poor patient outcomes and to develop effective 
preventative and therapeutic regimens for known 
tick bites, EM rashes and persistent disease. 
4,9,33,45,52,58,84,85
 Developing enhanced and sensitive 
assays targeting the diverse ranges of Borrelia 
species is warranted so as to support speedy 
diagnosis and treatment across the globe. Lastly, of 
great concern is the misdiagnosis and untreated 
tick borne diseases often diagnosed as chronic 
inflammatory aged related degeneration (for 
example arthritis, dementia, stroke), and 
notwithstanding the increased complications with 
aging for those with Lyme disease.  Particular 
efforts to better understand chronic Lyme are 
warranted, and within the sphere of supporting 
those whose lives and existence are severely 
compromised. Of note is low awareness in the few 
studies who investigated medical practitioner 
awareness of Lyme disease, highlighting the need 
for continued medical education to reduce 
misdiagnosis and inappropriate treatment.
2,75,86
 
The scientific uncertainty and the wide range of 
treatment modalities underscore the need for 
shared decision-making and enhanced support for 
those suffering from the disease.
3,87,88,89
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